EGFR signaling is involved in prostate cancer progression [6–9]; however, single-agent therapy using an EGFR tyrosine kinase inhibitor (TKI) was ineffective in castration-resistant prostate cancer (CRPC) [10]. Here, EGFR is linked to prostate carcinoma.